Breaking News, Collaborations & Alliances

Lexeo Therapeutics, Fujifilm Diosynth Biotechnologies Enter Cell & Gene Partnership

Collaboration to enable manufacturing of AAV-mediated gene therapies for LEXEO’s upcoming clinical trials, future IND-enabling studies and commercialization.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lexeo Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, and Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors, formed a collaboration to support the development and manufacturing of Lexeo’s AAV-mediated gene therapies.   Fujifilm Diosynth Biotechnologies will provide good manufacturing practice (GMP) pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters